Drugs like Genentech's Herceptin show what biotech can do when it comes to innovating blockbuster treatments, says Robert Langreth on the Forbes Treatments blog. Indeed by 2014, analysts predict that the top five bestselling drugs will have come from biotech. The problem is, no one wants to pay for the next generation of treatments, like those derived from stem cells, that could be hitting the market around 2020, Langreth says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.